A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.

@article{Blakely2009API,
  title={A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.},
  author={L. Johnetta Blakely and Lee S Schwartzberg and M. Joni Keaton and Fred Schnell and David H. Henry and Amanda L Epperson and Mark Stephen Walker},
  journal={Lung cancer},
  year={2009},
  volume={66 1},
  pages={97-102}
}
Pemetrexed and gemcitabine are both active agents for the treatment of locally advanced or metastatic NSCLC. We tested a novel biweekly combination of pemetrexed and gemcitabine for tolerability and efficacy in 45 elderly and/or poor performance status patients (44% female, mean age of 72.4 years) with measurable stage IIIB/IV NSCLC. Patients received biweekly cycles of pemetrexed 500 mg/m(2) IV over 10 min followed by gemcitabine 1500 mg/m(2) IV with vitamin B12 1000 microg IM, and folic acid… CONTINUE READING
6 Citations
27 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Similar Papers

Loading similar papers…